CytoSorbents (NSDQ:CTSO) announced today that it enrolled the first patient in a trial of its STAR-T trial for the DrugSorb-ATR system. Monmouth Junction, New Jersey-based CytoSorbents designed its DrugSorb-ATR antithrombotic removal system for the intraoperative removal of ticagrelor during cardiothoracic surgery. According to a CytoSorbents news release, the STAR-T (Safe and Timely Antithrombotic Removal-Ticagrelor) double-blind, […]
CytoSorbents Corp.
Aferetica, CytoSorbents gain EU nod for organ perfusion system
CytoSorbents (NSDQ:CTSO) and Aferetica today announced the European Union approval of Aferetica’s PerLife integrated ex-vivo system to perfuse, cleanse, recondition and preserve harvested kidneys and livers — including those that are usually discarded. Italian startup Aferetica designed its PerLife system is to improve organ function and viability while reducing the risk of primary graft failure and organ rejection. […]
CytoSorbents wins $1.1M DoD contract for universal plasma
CytoSorbents (OTC:CTSO) announced today that the U.S. Army has awarded it a $1.1 million contract to develop its HemoDefend-BGA adsorber. HemoDefend-BGA can rapidly remove more than 99% of anti-A and anti-B antibodies from plasma to create a “universal plasma” that could be administered to anyone, irrespective of blood type, while maintaining critical coagulation activity, according to […]
Cytosorbents announces $40m offering
CytoSorbents (OTC:CTSO) announced that it commenced an underwritten public offering of shares of its common stock worth $40 million. Monmouth Junction, N.J.-based CytoSorbents intends to grant underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock sold in connection with the offering as well, according to a […]
FDA grants breakthrough designation to CytoSorb blood purification tech
CytoSorbents (OTC:CTSO) announced that it received FDA breakthrough device designation for its CytoSorb blood purification technology for use during emergent and urgent cardiothoracic surgery. Monmouth Junction, N.J.-based CytoSorbents designed its CytoSorb technology to treat cytokine storm and deadly inflammation in critically-ill and cardiac surgery patients. The FDA breakthrough nod is for the use of CytoSorb for […]
FDA grants EUA for CytoSorb blood purification technology
CytoSorbents (OTC:CTSO) announced today that it received FDA emergency use authorization (EUA) for use of its CytoSorb blood purification technology in COVID-19 patients. With the authorization, Monmouth Junction, N.J.-based CytoSorbants is entitled to make CytoSorb commercially available to all U.S. hospitals for coronavirus patients aged 18 and older who are admitted to the intensive care unit […]
COVID-19 test development surges with pandemic
Companies around the world are racing to develop and distribute tests for COVID-19 to laboratories and to market other products and services they say can help patients and healthcare providers cope with the pandemic. On March 13, the FDA gave Thermo Fisher Scientific (NYSE:TMO) emergency use authorization (EUA) for a diagnostic test that certain U.S. laboratories […]
Safety board OKs continuation of CytoSorbents endocarditis trial
CytoSorbents (OTC:CTSO) said this week it the Data Safety Monitoring Board of its REMOVE trial gave the company the green light to continue the study after analyzing data from the first 50 patients. The German gov’t-funded randomized, controlled, multi-center 250-patient REMOVE trial, which was launched in late 2017, looked to explore the safety and efficacy of […]
Feds give CytoSorbents’ blood filter a shot at $3 million
CytoSorbents (NASDAQ: CTSO) said it has won another round of funding from the U.S. government to commercialize its HemoDefend red blood cell (RBC) transfusion filter. The critical-care immunotherapy company, based in Monmouth Junction, N.J., specializes in blood purification. The National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health, granted the three-year, Phase IIB […]
Could this system make more kidneys, livers usable for transplant?
An Italian startup has teamed with critical-care immunotherapy company CytoSorbents Corporation (NASDAQ: CTSO) on an integrated ex-vivo system to perfuse, cleanse, recondition and preserve harvested kidneys and livers — including those that are usually discarded. Aferetica srl (Mirandola, Italy) designed its PerLife system is to improve organ function and viability while reducing the risk of primary graft failure and […]
7 medtech stories we missed this week: June 15, 2018
From Cytosorbents opening a new U.S. manufacturing facility to DyAnsys received FDA clearance for a wearable to treat opioid withdrawals, here are seven medtech stories we missed this week but thought were still worth mentioning. 1. Cytosorbents opens new U.S. manufacturing facility CytoSorbents announced in a June 12 press release that it has opened a new […]
